Electrocore Inc is a medical technology company focused on developing non-invasive neuromodulation therapies to treat various conditions, particularly those related to the central nervous system
The company specializes in innovative solutions that utilize electrical stimulation to modulate nerve activity, aiming to address ailments such as migraines, cluster headaches, and other chronic pain conditions. By leveraging its proprietary technology, Electrocore seeks to provide patients with alternative treatment options that can enhance their quality of life while minimizing reliance on traditional pharmaceuticals. The company's commitment to research and development underscores its goal of advancing neuromodulation as a viable therapeutic approach in the healthcare landscape.
In this video, I review the market warnings I've shared over the past three weeks and how Friday's session confirmed negative divergences across key metrics signaling weakness.
In this video lesson, I review the resilient overall market, stocks on my radar for the short and long-term portfolio, and a new EOD swing trade, for Tuesday's session. Happy trading. Aloha.
LONDON, UNITED KINGDOM / ACCESSWIRE / September 4, 2024 / Ecora Resources PLC (LSE/TSX:ECOR) announces half year results for the six months ended 30 June 2024 which are available on both the Group's website at www.ecora-resources.com and on SEDAR at www.sedar.com.
RALEIGH, NC / ACCESSWIRE / September 25, 2023 / iAccess Alpha's Top 10 Best Ideas from the buyside virtual conference is taking place September 26th & 27th, 2023.
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million.
The Dow Jones closed lower by over 60 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
electroCore, Inc.’s (NASDAQ: ECOR) gammaCore non-invasive vagus nerve stimulation (“nVNS”) has been selected to be a part of studies on effects of cannabinoids and alternative care on athlete pain management and perfor
ROCKAWAY, N.J., March 21, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the results of a TruvagaTM focus group study conducted earlier this year. Based on a 30-day in-home use test by an independent third-party research firm, the Truvaga product helped its users improve stress, anxiety, sleep, energy, and mood.In the in-home focus group study, 34 participants were instructed to use the Truvaga product twice a day for 30 days to assess the product's benefits and overall user experience. Self-assessment evaluations were reported after 7 and 30 days. After 30 days, users reported the following:
